Philippines: Medical and Donor Requirements for Surrogacy
Short answer
A binding nationwide Philippine checklist for medical and gamete-donor requirements specific to surrogacy remains unconfirmed. Relevant administrative orders, professional rules or clinic conditions may nevertheless exist. Do not infer that a procedure is lawful merely because a surrogacy-specific prohibition was not located. General health, professional, consent, privacy and family-law rules still matter, and a clinic may refuse or limit treatment under its current professional or internal rules. Philippine law sets no universal statutory age, body-mass-index threshold, donor-anonymity rule, genetic-test panel, infectious-disease panel or surrogate obstetric-history threshold for this exact context. Every criterion should be labelled accurately as binding law, professional guidance, clinic policy or clinical recommendation. A 2025 scholarly perspective discusses the lack of a comprehensive ART/surrogacy framework; it is secondary analysis, not binding law, and should not be read as a categorical statutory prohibition.
Bills are proposals, not current screening rules
Official House records list both measures as pending with the Committee on Health: HB 1037, a proposal to establish a framework for the conduct and regulation of assisted reproductive technology (ART) and surrogacy procedures, has been pending since 29 July 2025; HB 8467, a proposal to regulate surrogacy and establish a Surrogacy Regulation Board, has been pending since 17 March 2026. The official bill text records HB 1037 as filed on 1 July 2025, and the House record lists HB 8467 as filed on 11 March 2026. These are proposals, not enacted law: neither creates binding screening requirements, authorizes a clinic or establishes parentage. Other Department of Health administrative issuances may be relevant; confirm the current requirements with Philippine counsel. A 2025 scholarly review describes a gap in comprehensive ART/surrogacy regulation, but it is secondary analysis, not a binding legal instrument.
What Article 164 actually says
Article 164 of the Family Code (Executive Order No. 209) addresses a child conceived through artificial insemination of a wife with the husband’s sperm, donor sperm, or both. It states that the child is likewise legitimate if both spouses authorized or ratified the insemination in a written instrument executed and signed before birth; the instrument is to be recorded in the civil registry with the birth certificate. This is a specific rule for the situation described in the article. It does not set donor medical tests, establish a general gamete-bank regime, or expressly resolve the status of a gestational surrogate, donated eggs, or every IVF arrangement. Do not treat a donor consent form or clinic letter as a substitute for analysing the actual family-law facts and parentage consequences.
Separate law from policy
| Source or rule type | What it supports | What it does not establish |
|---|---|---|
| Family Code, Article 164 | A written authorisation/ratification rule for the specified artificial-insemination situation involving a wife and her spouse or donor sperm. | A surrogacy-specific donor test panel, general egg-donation rule or complete parentage pathway for a gestational carrier. |
| Republic Act No. 10354 | General reproductive-health and informed-choice provisions. | A uniform statutory medical or genetic screening checklist for surrogacy or a complete ART eligibility code. |
| Professional guidance and clinic policy | May set access criteria, donor limits, tests, counselling and record procedures for the provider applying them. | A nationwide statute, unless an applicable binding instrument separately gives the rule that status. |
| Clinical due diligence | A reasoned, individualised assessment of the carrier, intended parents and donor material, with explained risks and consent. | Proof that any particular age, BMI, test or medical threshold is legally mandatory in the Philippines. |
Medical assessment of the person who will carry the pregnancy
A responsible clinical assessment should be individualised by a licensed reproductive-medicine specialist. Ask how the clinic evaluates the carrier’s medical and obstetric history, prior pregnancy outcomes, uterine and general health, existing conditions, medications, infection risks and pregnancy-related contraindications. Ask whether psychosocial counselling and an independent opportunity to ask questions are offered. These are prudent due-diligence questions, not a list of Philippine statutory surrogacy criteria verified. Do not accept a fixed checklist as legally mandatory unless the clinic identifies the exact current rule and its scope. Equally, do not assume that the absence of a statutory checklist makes medical assessment optional: clinical judgment, patient safety and professional obligations remain important.
Donor screening, consent and records
For sperm or egg donation, ask the clinic to provide its current written donor-screening protocol before treatment. It should explain what medical and family history is collected, which infectious-disease tests and genetic assessments are used, when testing occurs, whether repeat testing is required, how samples are identified and traced, and how results and residual risks are explained. The precise panel and timing should be confirmed by the treating specialist under current professional standards and individual circumstances; this article does not present any particular test as a statutory Philippine surrogacy requirement. A negative result cannot remove every risk. Obtain procedure-specific written informed consent from each person whose body, gametes or reproductive material will be involved. Ask for the consent, screening protocol, relevant test summaries, privacy notice and responsible physician’s licence details. The form should describe the actual procedure; generic wording about “IVF” or “donation” may not address a gestational-carrier arrangement. Ask whether third-party gametes are accepted at all, because professional guidance or a clinic’s own rules may be more restrictive than the general statutes located.
Privacy and research are separate questions
The Data Privacy Act of 2012 (Republic Act No. 10173) treats information about health, genetic information and a person’s sexual life as sensitive personal information. Processing must fit a lawful basis and the Act’s safeguards; consent is one possible basis, not a blanket licence for any future disclosure. Ask who holds donor and carrier records, why each item is collected, who receives it, how long it is retained, and how access or correction requests are handled. Separately, the Philippine Council for Health Research and Development publishes national ethical guidelines for research involving human participants. A research project involving ART must be assessed under the applicable research-ethics rules; those rules should not be casually converted into a universal clinical eligibility rule. The full current research text and effectivity should be checked if research is involved.
Practical checks and warning signs
Before committing, ask the clinic to identify in writing the legal basis, professional guideline and internal policy it applies to surrogacy and donor gametes. Verify the facility’s current Department of Health licence or authorisation, where applicable, and each clinician’s registration directly with the relevant authority; professional-society membership is not a government licence. Request dated copies of the protocols, consent and privacy documents, plus a written explanation of each test’s purpose, validity period, retesting rules, and how positive, borderline or inconclusive results affect eligibility. Ask which criteria apply separately to the carrier, donor and intended parents or recipients; do not assume everyone needs the same panel. Confirm who may access the records and whether participants can obtain their own records. Have Philippine counsel review the arrangement before embryo creation or transfer. Medical eligibility, enforceability of the arrangement and legal parentage are distinct questions. Treat unsupported claims that a test is legally required, that absence of a prohibition makes the arrangement automatically lawful, or that clinic accreditation guarantees parentage as red flags. Also be cautious about pressure to sign immediately, unclear sample records, refusal to explain tests, or promises of absolute donor anonymity. Ask what review or second-opinion route exists if treatment is delayed or declined. Ask whether tests are performed by a laboratory meeting the applicable quality requirements, whether an abnormal screening result is confirmed before it affects eligibility, and who explains residual risks and alternatives to the participant. If treatment is delayed or refused, request the specific criterion and reason in writing, whether repeat or confirmatory testing or independent review is available, and when the decision may be reconsidered. Keep dated protocols, consent forms, test summaries and correspondence together. Do not proceed with irreversible steps until a material test result or the applicable rule is resolved and properly documented. Ask the clinic to record its decision and the rule relied on in the patient file. These are due-diligence questions, not a statutory screening panel.
Bottom line and limits
For the Philippines, the defensible answer is not a universal list of legally mandated surrogate and donor tests. The sources establish relevant general family-law, reproductive-health and data-protection rules, but they do not establish a surrogacy-specific statutory screening panel. This is a qualified conclusion, not proof that every relevant administrative issuance or professional rule has been located; the full Department of Health issuance search and current professional guidelines remain to be checked. The proposals do not themselves create binding screening requirements. Specific clinical thresholds and donor panels must be verified against current professional guidance, clinic policy and the treating specialist’s assessment. This guide does not conclude that surrogacy or third-party gamete use is lawful, available, or enforceable in any particular case. Before any clinical step, obtain the current written rules and a Philippine legal opinion on the facts. Parentage, birth registration, foreign recognition and exit documentation are separate issues outside this article’s scope.
Sources and verification limits
- [S1] Executive Order No. 209 (Family Code of the Philippines) — Family Code text; Article 164 addresses artificial insemination of a wife and written spousal authorization.
- [S2] Republic Act No. 10354 (Responsible Parenthood and Reproductive Health Act of 2012) — Reproductive Health Act; general reproductive-health provisions, not a surrogacy-specific screening code.
- [S3] Republic Act No. 10173 (Data Privacy Act of 2012) — Data Privacy Act; health, genetic and sexual-life information are sensitive personal information.
- [S4] 2022 National Ethical Guidelines for Research Involving Human Participants — Official publication page for the 2022 national research-ethics guidelines; research rules are not a routine clinical checklist.
- [S5] House Bill No. 1037: proposed ART and surrogacy framework — Official bill text filed on 1 July 2025; the text is a proposal and does not establish current committee status.
- [S6] House of Representatives member page listing HB 8467
- [S7] Philippine Society for Reproductive Medicine: Publications and Guidelines
- [S8] The need for assisted reproductive technology regulations: a case for women in the Philippines (2025 perspective article)— Peer-reviewed 2025 discussion of the Philippine ART regulatory gap and professional self-regulation; secondary analysis, not binding law.
- [S9]Official House legislative record for HB 8467— Official House record: filed on 11 March 2026.
- [S10]Official House legislative record for HB 1037.
